MDL | - |
---|---|
Molecular Weight | 302.37 |
Molecular Formula | C16H22N4O2 |
SMILES | NC1=NC=C(CC2=CC(OC)=C(OC)C=C2C(C)C)C(N)=N1 |
RO-3 is a potent, CNS-penetrant, and orally active P2X 3 and P2X 2/3 antagonist with pIC 50 s of 5.9 and 7.0 for human homomultimeric P2X 3 and heteromultimeric P2X 2/3 receptors, respectively. RO-3 shows selectivity for P2X 3 and P2X 2/3 over all other functional homomultimeric P2X receptors (IC 50 >10 μM at P2X 1,2,4,5,7 ) [1] .
pIC50: 5.9 (human homomultimeric P2X 3 receptor); 7.0 (human heteromultimeric P2X 2/3 receptor) [1]
In a guinea pig ureter-afferent nerve preparation, and mouse bladder-pelvic nerve preparation, RO-3 dose-dependently reduces afferent nerve activity induced by distension or α,β-meATP
[1]
.
RO-3 has activity in several rodent models of pain, as well as in cystometry models optimized to measure various parameters associated with sensory regulation of the micturition reflex
[1]
.
RO-3 has moderate to high metabolic stability in rat and human hepatocytes and liver microsomes, and is highly permeable, orally bioavailable (14%), and has a reasonable in vivo plasma half-life (t
1/2
=0.41 h) in rats
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 125 mg/mL ( 413.40 mM ; ultrasonic and warming and heat to 60°C)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.3072 mL | 16.5360 mL | 33.0721 mL |
5 mM | 0.6614 mL | 3.3072 mL | 6.6144 mL |
10 mM | 0.3307 mL | 1.6536 mL | 3.3072 mL |
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (6.88 mM); Clear solution